Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma

被引：1
|
作者：
Tsilimigras, Diamantis I. [1 ]
Pawlik, Timothy M.
机构：
[1] Ohio State Univ, Wexner Med Ctr, Div Surg Oncol, Dept Surg, 410 W 10th Ave,Columbus, Columbus, OH 43210 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 23期
关键词：
ENDOTHELIAL GROWTH-FACTOR; DRUG-ELUTING BEADS; PHASE-III; EXPRESSION; EFFICACY; JAPANESE; TRIAL;
D O I：
10.21037/atm-20-7228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma
    Sinakos, Emmanouil
    Dedes, Ioannis
    Papalavrentios, Lavrentis
    Drevelegas, Antonios
    Akriviadis, Evangelos
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (04) : 511 - 512
  • [2] Transarterial chemoembolization and sorafenib in hepatocellular carcinoma
    Cabibbo, Giuseppe
    Tremosini, Silvia
    Galati, Giovanni
    Mazza, Giancarlo
    Gadaleta-Caldarola, Gennaro
    Lombardi, Giuseppe
    Antonucci, Michela
    Sacco, Rodolfo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (07) : 831 - 845
  • [3] Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Li, Lin
    Zhao, Wenzhuo
    Wang, Mengmeng
    Hu, Jie
    Wang, Enxin
    Zhao, Yan
    Liu, Lei
    BMC GASTROENTEROLOGY, 2018, 18
  • [4] Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Lin Li
    Wenzhuo Zhao
    Mengmeng Wang
    Jie Hu
    Enxin Wang
    Yan Zhao
    Lei Liu
    BMC Gastroenterology, 18
  • [5] Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis
    Chen, Anxin
    Li, Shijie
    Yao, Zhiyuan
    Hu, Jiahao
    Cao, Jiasheng
    Topatana, Win
    Juengpanich, Sarun
    Yu, Hong
    Shen, Jiliang
    Chen, Mingyu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (02) : 302 - 310
  • [6] THE SAFETY AND EFFICACY OF SORAFENIB COMBINED WITH TRANSARTERIAL CHEMOEMBOLIZATION FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Shao, W.
    Cong, N.
    Song, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 161 - 161
  • [7] Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma
    Li, Yong
    Zheng, You-Bing
    Zhao, Wei
    Liu, Bing
    Hu, Bao-Shan
    He, Xu
    Huang, Jian-Wen
    Lu, Li-Gong
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [8] Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma
    Yong Li
    You-Bing Zheng
    Wei Zhao
    Bing Liu
    Bao-Shan Hu
    Xu He
    Jian-Wen Huang
    Li-Gong Lu
    Medical Oncology, 2013, 30
  • [9] Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
    Zhang, Lei
    Xia, Wei
    Yan, Zhi-Ping
    Sun, Jun-Hui
    Zhong, Bin-Yan
    Hou, Zhong-Heng
    Yang, Min-Jie
    Zhou, Guan-Hui
    Wang, Wan-Sheng
    Zhao, Xing-Yu
    Jian, Jun-Ming
    Huang, Peng
    Zhang, Rui
    Zhang, Shen
    Zhang, Jia-Yi
    Li, Zhi
    Zhu, Xiao-Li
    Gao, Xin
    Ni, Cai-Fang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [10] Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study
    Zhang, Jin-Xing
    Chen, Yu-Xing
    Zhou, Chun-Gao
    Liu, Jin
    Liu, Sheng
    Shi, Hai-Bin
    Zu, Qing-Quan
    HEPATOLOGY RESEARCH, 2022, 52 (09) : 794 - 803
12345